London, United Kingdom
Avillion Life Sciences, founded in 2013, is a UK-based company pioneering a unique approach in the Health Care and Pharmaceutical industries. With the slogan “Accelerating global drug development through successful partnering for patient benefit,” Avillion focuses on late-phase clinical projects in both the EU and US markets, aiming to expedite therapeutics' availability for approval and distribution.
Avillion's innovative model offers a distinct value proposition for firms looking to partner on late-stage drug development. Their emphasis is on bridging the gap between clinical trial completion and regulatory approvals, thus accelerating the time it takes for life-saving medications to reach the market.
Their last recorded investment was a Venture Round on 28 January 2013, led by renowned investors Abingworth and Clarus Ventures. This strategic backing underscores the confidence in Avillion's model and its potential for impactful growth globally.
-(OTCQX:CPHRF)-logo.jpg "Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX:CPHRF)"){kind=logo}
Beihai Biotech
Fabre-Kramer Pharmaceuticals, Inc.